Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin effects on insulin and beta-cell sensitivity in T2D and MODY
NCT04531631Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dorzagliatin in type 2 diabetes mellitus (T2DM), Maturity Onset Diabetes of the Young (MODY), sponsored by The Chinese University of Hong Kong. Started Sep 2020; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)Maturity Onset Diabetes of the Young (MODY)
Beyond the preview
Go deeper on NCT04531631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531631.